FDA to Decide on Deramiocel Approval November 22

The regulatory decision follows a strategic application pivot focused on upper-limb function data from the HOPE-3 trial.

Updated on Oct. 21, 2026 in Biotech

FDA to Decide on Deramiocel Approval November 22

Live Poll

Is now a good time for you to invest in pharmaceutical companies awaiting FDA drug approval?

The FDA has set a new decision date of November 22, 2026, for Capricor Therapeutics to receive approval for its therapy Deramiocel. The agency delayed the deadline after the company submitted a major amendment to its application based on 24-month clinical trial data.

Why it matters

The delay reflects a strategic pivot for the drug, which the company has narrowed to focus on upper-limb function rather than cardiomyopathy following a negative advisory committee vote. The shift represents a final effort to salvage the therapy after earlier regulatory setbacks.

The application now includes 24-month clinical analyses from the HOPE-3 trial, a pivot from previous iterations of the data package. This amendment resulted in the postponement of the final FDA decision until November 22, 2026.

The players

Capricor Therapeutics

A biotech firm focused on cell-based therapies for Duchenne muscular dystrophy and other cardiac-related conditions.

FDA

The federal agency responsible for regulating pharmaceuticals and biologics in the United States.

H.C. Wainwright

An investment banking firm that currently maintains a cautious outlook on the approval prospects for Deramiocel.

Roth Capital

An investment bank that has suggested the possibility of a second advisory committee review regarding upper-limb preservation.

The details

Capricor Therapeutics is utilizing data from its HOPE-3 trial, a study evaluating the safety and efficacy of its cell-based therapy in patients. The company has refined its application label to prioritize upper-limb function improvements, departing from its earlier focus on cardiomyopathy. This regulatory filing serves as a major amendment, requiring the agency to conduct additional reviews of the long-term clinical outcomes.

July 2025: The FDA issued an initial rejection of the first application.
July 2026: An advisory committee voted 9-3 against the efficacy of the drug.
October 2026: Capricor stock experienced a 38% monthly decline.
November 22, 2026: The FDA is scheduled to render a decision on approval.

The Tech Race

This timeline follows the July 2026 advisory committee vote that cast doubt on the therapy's overall effectiveness. The company is now racing against the November deadline to demonstrate that its focused data on upper-limb function meets regulatory standards.

Investors and stakeholders are watching the November 22 decision to determine the future availability of this therapy. Analysts are currently divided, with six out of ten rating the stock as a Hold while waiting for the final regulatory outcome.

The takeaway

The company’s survival relies on this final regulatory window, with market analysts projecting a $27 average price target. Observers should track the November 22 FDA announcement to see if the amended trial data satisfies agency standards.